Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma

Giuseppe Lucarelli, Monica Rutigliano, Matteo Ferro, Andrea Giglio, Angelica Intini, Francesco Triggiano, Silvano Palazzo, Margherita Gigante, Giuseppe Castellano, Elena Ranieri, Carlo Buonerba, Daniela Terracciano, Francesca Sanguedolce, Anna Napoli, Eugenio Maiorano, Franco Morelli, Pasquale Ditonno, Michele Battaglia

Research output: Contribution to journalArticlepeer-review


Objective To investigate the expression of the kynurenine (KYN) pathway components and the prognostic role of the KYN-to-tryptophan ratio (KTR) in a cohort of patients with clear cell renal cell carcinoma (ccRCC). Materials and methods The expression of KYN pathway components was investigated by tissue microarray-based immunohistochemistry, indirect immunofluorescence, and confocal microscopy analysis in 100 ccRCC cases and 30 normal renal samples. The role of this pathway in sustaining cancer cell proliferation, migration, and chemoresistance was evaluated. In addition, tryptophan and KYN concentrations and their ratio were measured in serum of 195 patients with ccRCC using a sandwich enzyme-linked immunosorbent assay. The role of KTR as a prognostic factor for ccRCC cancer-specific survival (CSS) and progression-free survival (PFS) was assessed. Results Tissue microarray-based immunohistochemistry and indirect immunofluorescence staining showed an increased signal for KYN pathway components in ccRCC. Kaplan-Meier curves showed significant differences in CSS and PFS among groups of patients with high vs. low KTR. In particular, patients with high KTR values had a 5-year survival rate of 76.9% as compared with 92.3% for subjects with low levels (P < 0.0001). Similar findings were observed for PFS (72.8% vs. 96.8% at 5 y). At multivariate analysis, KTR was an independent adverse prognostic factor for CSS (hazard ratio = 1.24, P = 0.001), and PFS (hazard ratio = 1.14, P = 0.001). Conclusions The involvement of the KYN pathway enzymes and catabolites in ccRCC occurs via both immune and nonimmune mechanisms. Our data suggest that KTR could serve as a marker of ccRCC aggressiveness and as a prognostic factor for CSS and PFS.

Original languageEnglish
Pages (from-to)461.e15-461.e27
JournalUrologic Oncology: Seminars and Original Investigations
Issue number7
Publication statusPublished - Jul 1 2017


  • Aryl hydrocarbon receptor
  • Cancer metabolism
  • Indoleamine 2,3-dioxygenase
  • Kynurenine
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma'. Together they form a unique fingerprint.

Cite this